ArticleFrontiers in pharmacology2022
Analysis of the correlation between non-alcoholic fatty liver disease and the risk of colorectal neoplasms.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies.Frontiers in oncology · 2024Pooled it
- Endoscopic characterization and development of a prediction model for colorectal adenomatous polyps.World journal of gastrointestinal surgery · 2026Article
- Analysis of the incidence and risk factors of colorectal polyps in patients with chronic hepatitis B complicated by non - alcoholic fatty liver disease.BMC gastroenterology · 2026Article
- Development and Validation of a Traditional Chinese Medicine Constitution-Based Risk Score for Advanced Colorectal Neoplasia in Asymptomatic Chinese Adults.Cancer management and research · 2026Article
- Killing hepatocellular carcinoma in the NAFLD/NASH stage: a comprehensive perspective on targeting regulated cell death.Cell death discovery · 2025Review
- Integrating molecular pathway with genome-wide association data for causality identification in breast cancer.Discover oncology · 2024Article
- Editorial: Ferroptosis in cancer and Beyond-volume II.Frontiers in molecular biosciences · 2023Article
- Editorial: Ferroptosis in cancer and beyond.Frontiers in molecular biosciences · 2022Article
- Nonalcoholic Fatty Liver Disease and Male Sex are Risk Factors for Colorectal Adenoma: a Retrospective Analysis.Acta gastroenterologica LatinoamericanaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims at assessing the potential association between non-alcoholic fatty liver disease (NAFLD) and colorectal neoplasms (CRN). PubMed, Cochrane Library, and Embase were searched for cohort studies. 14 cohort studies with a total population of 38,761,773 were included for meta-analysis after selection. The results showed that NAFLD is related to an increased risk of CRN (OR = 1.23; 95% CI: 1.14-1.32; I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.